Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: Can it be predicted using clinical parameters?

Cancer

Volumn 107, Issue 7, 2006, Pages 1503-1510

  Spiess, Philippe E ^a   Brown, Gordon A ^a   Pisters, Louis L ^a   Liu, Ping ^a   Tu, Shi Ming ^a   Evans, James G ^a   Kamat, Ashish M ^a   Black, Peter ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Postchemotherapy; Predictors; Retroperitoneal lymph node dissection; Risk categorization; Viable tumor

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; VINBLASTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CORRELATION ANALYSIS; EARLY CANCER; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON SEMINOMATOUS GERMINOMA; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL;

ADULT; ALPHA-FETOPROTEINS; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY, SURGICAL; PROGNOSIS; RETROPERITONEAL SPACE; RISK; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749604831     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22181     Document Type: Article

References (20)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2002 [based on November 2004 SEER data submission; posted to the SEER web site 2005]. Bethesda: National Cancer Institute, 2005.
2. [No authors listed.] International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594-603.
3. Steyerberg EW, Ketzer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor, multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995;13:1177-1187.
4. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol. 2002;20:262-271.
5. Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16:65-71.
6. Rollender A, Stenwig EA, Ous S, Fossa SD. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy. Eur Urol 1997;31:141-147.
7. Onozawa M, Kawai K, Yamamoto T, et al. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer. Int J Urol. 2004;11: 535-541.
8. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21:3310-3317.
9. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol. 1985;3:326-335.
10. Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rates in disseminated testicular non-seminomatous germ-cell tumors: final results of a Phase III randomized trial. Ann Oncol. 2002;13: 125-134.
11. Fizazi K, Do KA, Wang X, Finn L, Kim J, Daliani D. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors. Br J Cancer. 2002;86:1555-1560.
12. Prow DM, Amato RJ, Jones DM, Logothetis CJ. Carboplatin, etoposide, and bleomycin (CEB) combination chemotherapy for the treatment of small volume (SV) metastatic non-seminomatous germ cell tumor of the testis (NSGCT). Proc Am Soc Clin Oncol. 1997;16:340a. Abstract 1217.
13. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23:2781-2788.
14. Kaplan EL, Meier EP. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Cox D. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
16. Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer. 1998;83:1409-1419.
17. Fossa SD, Aass N, Ous S, et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol. 1989;142:1239-1242.
18. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15:1377-1399.
19. van Dijk MR, Steyerberg EW, Stenning SP, Dusseldorp E, Habbema JD. Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer. 2004;90: 1176-1183.
20. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated non-seminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol. 2001;19:2647-2657.